Wolverine Trading, LLC Bei Gene, Ltd. Transaction History
Wolverine Trading, LLC
- $93.9 Billion
- Q3 2024
A detailed history of Wolverine Trading, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Wolverine Trading, LLC holds 1,000 shares of BGNE stock, worth $215,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000Holding current value
$215,000% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.27 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.38 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.11 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$1.07 Billion0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$797 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.3B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...